Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonadherence to drug therapy poses a significant problem in the treatment of patients with presumed resistant hypertension. It has been shown that therapeutic drug monitoring (TDM) is a useful tool for detecting nonadherence and identifying barriers to treatment adherence, leading to effective blood pressure (BP) control. However, the cost-effectiveness of TDM in the management of resistant hypertension has not been investigated. METHOD: A Markov model was used to evaluate life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in resistant hypertension patients receiving either TDM optimized therapy or standard best medical therapy. The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and mortality. Cost analyses were performed from a payer's perspective. Deterministic and probabilistic sensitivity analyses were conducted. RESULTS: In the age group of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at additional costs of €3854 and €3922, respectively. Given a willingness-to-pay threshold of €35,000 per QALY gained, the probability of TDM being cost-effective was 95% or more in all age groups from 30 to 90 years. Results were influenced mostly by the frequency of TDM testing, the rate of nonresponders to TDM, and the magnitude of effect of TDM on BP. CONCLUSION: Therapeutic drug monitoring presents a potential cost-effective healthcare intervention in patients diagnosed with resistant hypertension. Importantly, this finding is valid for a wide range of patients, independent of sex and age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 2×
“All calculations were based on the Systemic Coronary Risk Evaluation (SCORE) equations [18].”
MethodA Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Resistant hypertension? Assessment of adherence by toxicological urine analysis
Jung, O., Gechter, J. L., Wunder, C., Paulke, A., Bartel, C., Geiger, H., & Toennes, S. W. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835e2286 · Cited by 474
The prognosis of heart failure in the general population: the Rotterdam Study
Mosterd, A. (2001) · European Heart Journal · doi:10.1053/euhj.2000.2533 · Cited by 470
Tomaszewski, M., White, C., Patel, P., Masca, N., Damani, R., Hepworth, J., Samani, N. J., Gupta, P., Madira, W., Stanley, A., et al. (2014) · Heart · doi:10.1136/heartjnl-2013-305063 · Cited by 404
High prevalence of cardiac and extracardiac target organ damage in refractory hypertension
Cuspidi, C., Macca, G., Sampieri, L., Michev, I., Salerno, M., Fusi, V., Severgnini, B., Meani, S., Magrini, F., & Zanchetti, A. (2001) · Journal of Hypertension · doi:10.1097/00004872-200111000-00018 · Cited by 303
Hillen, T., Coshall, C., Tilling, K., Rudd, A. G., McGovern, R., & Wolfe, C. D. A. (2003) · Stroke · doi:10.1161/01.str.0000072985.24967.7f · Cited by 298
Cited by
Berra, E., Azizi, M., Capron, A., Høieggen, A., Rabbia, F., Kjeldsen, S. E., Staessen, J. A., Wallemacq, P., & Persu, A. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07464 · Cited by 195
How to Screen for Non-Adherence to Antihypertensive Therapy
Gupta, P., Patel, P., Horne, R., Buchanan, H., Williams, B., & Tomaszewski, M. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0697-7 · Cited by 84
Apparent treatment-resistant hypertension – patient–physician relationship and ethical issues
Mariampillai, J. E., Eskås, P. A., Heimark, S., Larstorp, A. C. K., Fadl Elmula, F. E. M., Høieggen, A., & Nortvedt, P. (2017) · Blood Pressure · doi:10.1080/08037051.2016.1277129 · Cited by 16
Metadata
- Authors
- Chung, O., Vongpatanasin, W., Bonaventura, K., Lotan, Y., Sohns, C., Haverkamp, W., & Dorenkamp, M.
- Venue
- Journal of Hypertension
- Published
- 2014-12
- Volume
- 32
- Issue
- 12
- Pages
- 2411-2421
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2029998230
- Cited by
- 46
- References
- 8
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. https://app.cochat.ai/papers/10.1097/hjh.0000000000000346
- The paper
- Chung, O., Vongpatanasin, W., Bonaventura, K., Lotan, Y., Sohns, C., Haverkamp, W., & Dorenkamp, M. (2014). Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000000346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.